Zobrazeno 1 - 10 of 103 pro vyhledávání: '"Swantje, Held"'
1
Akademický článek
Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial
Autor: Meinolf Karthaus, Volker Heinemann, Jorge Riera-Knorrenschild, Albrecht Kretzschmar, Manfred Welslau, Ulrich Kaiser, Henning Pelz, Thomas J. Ettrich, Swantje Held, Linde Kehmann, Jürgen Hess, Timo Reisländer, Lena Weiss, on behalf of the TALLISUR study group
Publikováno v: BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background In the pivotal phase III RECOURSE trial, trifluridine/tipiracil (FTD/TPI) improved progression-free and overall survival (PFS, OS) of patients with pre-treated metastatic colorectal cancer (mCRC). Subsequently, the TALLISUR trial
Externí odkaz: https://doaj.org/article/bfc837e7c22d4f35917763b74a09a350
Zobrazit plný text záznamu
2
Akademický článek
Integrated Analysis of the RASH Study with the Use of the 'Burden of Therapy' (BOTh®TM) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer
Autor: Klara Dorman, Stefan Boeck, Robert J. Snijder, Jens T. Siveke, Michael Schenk, Julia Mayerle, Karel Caca, Jens Freiberg-Richter, Ludwig Fischer von Weikersthal, Frank Kullmann, Anke Reinacher-Schick, Martin Fuchs, Stephan Kanzler, Volker Kunzmann, Thomas J. Ettrich, Danmei Zhang, Swantje Held, Ayad Abdul-Ahad, Michael von Bergwelt-Baildon, Volker Heinemann, Michael Haas
Publikováno v: Current Oncology, Vol 30, Iss 6, Pp 5828-5834 (2023)
This analysis of the RASH trial (NCT01729481) aimed at gaining a better understanding of the “Burden of Therapy” (BOTh®TM) in pancreatic ductal adenocarcinoma (PDAC). In the RASH study, 150 patients with newly diagnosed metastatic PDAC were trea
Externí odkaz: https://doaj.org/article/d4ab867951864e49ad0edeb7b333eb01
Zobrazit plný text záznamu
3
Akademický článek
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)
Autor: Florian Gebauer, Alexander Ioannis Damanakis, Felix Popp, Alexander Quaas, Fabian Kütting, Katrin Lutz, Swantje Held, Burkhard Deuß, Tobias Göser, Dirk Waldschmidt, Christiane Bruns
Publikováno v: BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background According to current guidelines, treatment of patients with hepatic oligometastasis in pancreatic cancer is not reflected and systemic chemotherapy is recommended in those patients. Retrospective data suggest beneficial outcomes i
Externí odkaz: https://doaj.org/article/616c088826884c7d99c7984e35c6d4f5
Zobrazit plný text záznamu
4
Akademický článek
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial
Autor: Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Ullrich Graeven, Kathrin Heinrich, Swantje Held, Arndt Stahler, Annabel Helga Sophie Alig, Ivan Jelas, Jobst C. von Einem, Sebastian Stintzing, Clemens Giessen-Jung, Dominik P. Modest
Publikováno v: Frontiers in Oncology, Vol 12 (2022)
IntroductionEarly tumor shrinkage (ETS), depth of response (DpR), and time to DpR represent exploratory endpoints that may serve as early efficacy parameters and predictors of long-term outcome in metastatic colorectal cancer (mCRC). We analyzed thes
Externí odkaz: https://doaj.org/article/02c58eab2dbe4e41985915f0822765da
Zobrazit plný text záznamu
6
Akademický článek
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)
Autor: Daniel Heudobler, Christian Schulz, Jürgen R. Fischer, Peter Staib, Thomas Wehler, Thomas Südhoff, Thomas Schichtl, Jochen Wilke, Joachim Hahn, Florian Lüke, Martin Vogelhuber, Sebastian Klobuch, Tobias Pukrop, Wolfgang Herr, Swantje Held, Kristine Beckers, Gauthier Bouche, Albrecht Reichle
Publikováno v: Frontiers in Pharmacology, Vol 12 (2021)
Background: Most non-small cell lung cancers occur in elderly and frequently comorbid patients. Therefore, it is necessary to evaluate the efficacy of biomodulatory active therapy regimen, concertedly interfering with tumor-associated homeostatic pat
Externí odkaz: https://doaj.org/article/120f96cd72e34bd0a075f9e90dccdae2
Zobrazit plný text záznamu
7
Akademický článek
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer
Autor: Martin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, Niels Reinmuth, Martin Sebastian, Monika Serke, Cornelius Florian Waller, Michael Thomas, Jochen Eggert, Gerald Schmid-Bindert, Mathias Hoiczyk, Daniel Christian Christoph, Martin Kimmich, Burkhard Deuß, Stephanie Seifert, Swantje Held, Martin Schuler, Thomas Herold, Frank Breitenbuecher, Wilfried Ernst Erich Eberhardt
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Pemetrexed and cisplatin is a first-line standard in non-squamous non-small-cell lung cancer without targetable mutations. It became the backbone of checkpoint-inhibitor–chemotherapy combinations. Single high doses of cisplatin pose tox
Externí odkaz: https://doaj.org/article/d242cd41cb214934942f7de020430e08
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje